Peptides and Biohacking

Peptides are short amino-acid chains, and many are impeccable medicine: insulin, GLP-1 agonists and oxytocin are all peptides. The gray market sells something else — compounds like BPC-157, TB-500, ipamorelin, CJC-1295 and epitalon, marketed for injury healing, growth-hormone release, fat loss and longevity, none approved by any major regulator for any indication. The flagship, BPC-157 ('body protection compound'), has a substantial rodent literature on gut and tendon healing and essentially zero published randomised human trials for the uses it is sold for. The gap between animal data and human evidence is precisely the gap drug development exists to cross, and these compounds have not crossed it — some never entered it.

The distribution model is a legal fiction operating in plain sight: vials labelled 'for research use only — not for human consumption' sold on websites whose customer base is visibly injecting them, guided by dosing protocols from podcasts, forums and influencer channels. The label transfers all liability to the buyer while evading drug regulation entirely — no manufacturing standards, no sterility requirements, no potency verification, no adverse-event reporting. Regulators have begun closing in: the FDA moved BPC-157 and several other popular peptides into its highest-concern compounding category in 2023, cutting off the licensed-pharmacy supply and pushing the market further into the unregulated channel it began in.

When researchers and anti-doping laboratories have tested gray-market peptide products, the results are what unregulated manufacture predicts: wrong doses, wrong compounds, bacterial endotoxin contamination and sometimes no active ingredient at all. Published analyses of 'research chemical' peptides have found large fractions mislabelled in identity or quantity. For injected products this is not a consumer-protection footnote — non-sterile injection risks abscess and sepsis, endotoxin causes febrile reactions, and unknown potency makes even a theoretically safe compound unsafe in practice. Whatever one believes about BPC-157's rodent pharmacology, the actual product in the actual vial is an unknown by construction.

Elite sport answered early: growth-hormone secretagogues and healing peptides populate the WADA prohibited list — BPC-157 was added explicitly in 2022 — and athletes have tested positive through contaminated supplements, which is its own warning about supply purity. The pharmacological concern for civilians is the same one that makes these compounds performance-enhancing: secretagogues like ipamorelin and CJC-1295 raise growth hormone and IGF-1 chronically, an axis with theoretical oncological implications nobody has studied at gray-market doses over gray-market durations, because no one is studying any of it. Melanotan II — the injectable tanning peptide — adds documented acute harms: nausea, priapism, and dermatological concern over changing moles.

The peptide economy rides a broader biohacking culture — optimisation framing, distrust of institutional medicine's pace, podcast authorities, and the felt reasonableness of 'the studies just have not been done, but the mechanism makes sense'. Parts of the impulse are healthy: sleep, exercise and diet optimisation are biohacking too, and cost nothing. The peptide layer inverts the risk calculus — injecting unverified compounds of unknown purity for theoretical benefits — while borrowing the vocabulary of experimentation without its substance: no controls, no measurement, no adverse-event capture, an n-of-1 with no data collection. The sellers' economics are the supplement industry's with needles: high margins, no efficacy obligation, and the customer as the trial.

No gray-market peptide has human evidence remotely justifying self-injection: BPC-157's trials are rodent, the secretagogues manipulate a growth axis with unstudied long-term implications, and the vial's actual contents are unverified regardless of the compound's theoretical merits. Anyone determined to pursue peptide therapeutics should do it the only way that generates knowledge — through registered clinical trials or a licensed physician prescribing approved products. Athletes should assume any peptide product can end a career via the prohibited list or contamination. And the universally available performance stack — sleep, progressive training, protein, patience — outperforms the vial on every published measure, including cost.